Showing results (321-330 of 527) with videos related to

Sort By:
Pageof 53
Discover Oncology|July 31, 2025
Prognostic value of FDG PET/CT in special types of breast cancer with non-favorable histologyMutsumi Fujimoto, Momoko Takaya, Kanako Suzuki, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|April 12, 2025
Comparative oncological features of centrally and peripherally located small-sized radiologically solid-dominant non-small-cell lung cancerNorifumi Tsubokawa, Takahiro Mimae, Yoshihiro Miyata, et al.
World Journal of Surgery|April 30, 2024
Association between prognosis and lymph node status using <sup>18</sup>F-fluorodeoxyglucose-positron emission tomography in esophageal squamous cell carcinoma treated with esophagectomy post-neoadjuvant chemotherapyManato Ohsawa, Yoichi Hamai, Manabu Emi, et al.
Journal of Clinical Medicine|December 23, 2022
Leukocyte Telomeric G-Tail Length Shortening Is Associated with Esophageal Cancer RecurrenceJiayan Han, Soichiro Hayashi, Ryou-U Takahashi, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|August 16, 2003
Expression of the TSLC1 adhesion molecule in pulmonary epithelium and its down-regulation in pulmonary adenocarcinoma other than bronchioloalveolar carcinomaAkihiko Ito, Morihito Okada, Kazuya Uchino, et al.
The American Journal of Surgical Pathology|June 5, 2020
SOX6 is a Novel Immunohistochemical Marker for Differential Diagnosis of Epithelioid Mesothelioma From Lung AdenocarcinomaTakahiro Kambara, Vishwa J Amatya, Kei Kushitani, et al.
Histopathology|October 18, 2018
Mucin 21 is a novel, negative immunohistochemical marker for epithelioid mesothelioma for its differentiation from lung adenocarcinomaYuichiro Kai, Vishwa J Amatya, Kei Kushitani, et al.
Anticancer Research|January 30, 2026
Differences of HER2 Status by HercepTest and PATHWAY 4B5 Immunohistochemical Assays in Breast CancerShinsuke Sasada, Momoko Takaya, Kanako Suzuki, et al.
The American Journal of Surgical Pathology|October 30, 2023
SPARC Is a Novel Positive Immunohistochemical Marker of Epithelioid Mesothelioma to Differentiate It From Lung Adenocarcinoma and/or Squamous Cell CarcinomaTetsuya Nakagiri, Vishwa J Amatya, Kei Kushitani, et al.
Japanese Journal of Clinical Oncology|November 28, 2017
A randomized Phase III trial of lobe-specific vs. systematic nodal dissection for clinical Stage I-II non-small cell lung cancer (JCOG1413)Tomoyuki Hishida, Hisashi Saji, Shun-Ichi Watanabe, et al.
Pageof 53